Andere Sprachen MannKind Corporation

Aktien

A2DMZL

US56400P7069

MNKD

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:04 31.05.2024			% 5 Tage	% 1. Jan.
4,675 ^USD	+3,89 %		-2,20 %	+28,43 %

29.05.	MannKind vereinbart Cross-License-Deal mit Pulmatrix	MT
29.05.	Pulmatrix, Inc. kundigt gegenseitige Lizenzvereinbarung und Ubertragung des Labors an MannKind Corporation an	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

MannKind Agrees to Cross License Deal With Pulmatrix	29.05.
Pulmatrix, Inc. Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	29.05.
Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024	08.05.
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment	06.05.
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease	06.05.
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	30.04.
MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	29.04.
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease	29.04.
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects	26.03.
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	11.03.
Transcript : MannKind Corporation, Q4 2023 Earnings Call, Feb 27, 2024	27.02.
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27.02.
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	15.02.
Transcript : MannKind Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	11.01.
Transcript : MannKind Corporation - Special Call	03.01.
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02.01.
MannKind Sells 1% Royalty on Tyvaso DPI Net Sales for Up to $200 Million	02.01.
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals	28.12.
Mannkind Insider Sold Shares Worth $801,928, According to a Recent SEC Filing	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MannKind Corporation

Aktien

A2DMZL

US56400P7069

MNKD

Andere Sprachen

Filter